Robin Liechti

SIB Swiss Institute of Bioinformatics — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index4.8kcitations77works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(15), Single-cell and spatial transcriptomics(11), Insect-Plant Interactions and Control(10), Cancer Immunotherapy and Biomarkers(10), Plant Parasitism and Resistance(9)

Publications77 total

Genomic and immune landscape of recurrent and/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment
Cancer Immunology Research·2026Open Access
Supplementary Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database
2025Open Access
Cellohood: multi-granular discovery of cellular neighborhoods with a permutation-invariant set transformer auto-encoder
2025Open Access
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Universität Zürich, ZORA·2025Open Access
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Cell Reports Methods·2025· 1 citedOpen Access
Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck: A multi-omics IMMUCAN/EORTC analysis.
Journal of Clinical Oncology·2025
Abstract 1177: Tumor-associated macrophages and clinical outcomes to immunotherapy
Cancer Research·2025
257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Annals of Oncology·2024Open Access
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Journal of Hepatology·2024· 39 cited
186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project
Immuno-Oncology Technology·2023Open Access
1P Integrated data analysis within IMMUcan identifies prognostic features of early NSCLC
Immuno-Oncology Technology·2023Open Access
176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Immuno-Oncology Technology·2023Open Access
195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches
Immuno-Oncology Technology·2023· 1 citedOpen Access
199P Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Immuno-Oncology Technology·2023Open Access
179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Immuno-Oncology Technology·2023Open Access
2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Annals of Oncology·2023· 3 citedOpen Access
Abstract 4522: Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study
Cancer Research·2023
Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database
2023Open Access
Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database
2023Open Access
Supplementary Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Ioannis Xénarios(27), Dmitry Kuznetsov(10), Edward E. Farmer(10), Lou Götz(8), Nicolas Guex(7), Isaac Crespo(7), Mark Ibberson(6), Lorella Marselli(6), Piero Marchetti(6), Marie Morfouace(5), Anke M. Schulte(4), Bernard Thorens(4), Mauro Delorenzi(4), Aurélie Gfeller(4), Marco Bugliani(4), Alan Bridge(4), Sylvie Rusakiewicz(4), Henoch S. Hong(4), Leonore Wigger(3), Winship Herr(3)